<sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital
Aim: To perform a comprehensive analysis of discordances between contrast-enhanced CT (ceCT) and <sup>18</sup>F-FDG PET/CT in the evaluation of the extra-cerebral treatment monitoring in patients with stage IV melanoma. Materials and methods: We conducted a retrospective monocentric obse...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/7/1198 |
| _version_ | 1797527288654331904 |
|---|---|
| author | Jean-Baptiste Le Goubey Charline Lasnon Ines Nakouri Laure Césaire Michel de Pontville Catherine Nganoa Diane Kottler Nicolas Aide |
| author_facet | Jean-Baptiste Le Goubey Charline Lasnon Ines Nakouri Laure Césaire Michel de Pontville Catherine Nganoa Diane Kottler Nicolas Aide |
| author_sort | Jean-Baptiste Le Goubey |
| collection | DOAJ |
| description | Aim: To perform a comprehensive analysis of discordances between contrast-enhanced CT (ceCT) and <sup>18</sup>F-FDG PET/CT in the evaluation of the extra-cerebral treatment monitoring in patients with stage IV melanoma. Materials and methods: We conducted a retrospective monocentric observational study over a 3-year period in patients referred for <sup>18</sup>F-FDG PET/CT and ceCT in the framework of therapy monitoring of immune checkpoint (ICIs) as of January 2017. Imaging reports were analyzed by two physicians in consensus. The anatomical site responsible for discordances, as well as induced changes in treatment were noted. Results: Eighty patients were included and 195 pairs of scans analyzed. Overall, discordances occurred in 65 cases (33%). Eighty percent of the discordances (52/65) were due to <sup>18</sup>F-FDG PET/CT scans upstaging the patient. Amongst these discordances, 17/52 (33%) led to change in patient’s management, the most frequent being radiotherapy of a progressing site. ceCT represented 13/65 (20%) of discordances and induced changes in patients’ management in 2/13 cases (15%). The most frequent anatomical site involved was subcutaneous for <sup>18</sup>F-FDG PET/CT findings and lung or liver for ceCT. Conclusions: Treatment monitoring with <sup>18</sup>F-FDG PET/CT is more efficient than ceCT and has a greater impact in patient’s management. |
| first_indexed | 2024-03-10T09:41:49Z |
| format | Article |
| id | doaj.art-1b9291bce779471281c406e9b88d7b73 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T09:41:49Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-1b9291bce779471281c406e9b88d7b732023-11-22T03:34:09ZengMDPI AGDiagnostics2075-44182021-07-01117119810.3390/diagnostics11071198<sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University HospitalJean-Baptiste Le Goubey0Charline Lasnon1Ines Nakouri2Laure Césaire3Michel de Pontville4Catherine Nganoa5Diane Kottler6Nicolas Aide7Dermatology Department, University Hospital, 14000 Caen, FranceNuclear Medicine Department, François Baclesse Cancer Centre, 14000 Caen, FranceDermatology Department, University Hospital, 14000 Caen, FranceDermatology Department, University Hospital, 14000 Caen, FranceDermatology Department, University Hospital, 14000 Caen, FranceNuclear Medicine Department, University Hospital, 14000 Caen, FranceDermatology Department, University Hospital, 14000 Caen, FranceINSERM ANTICIPE U 1086, Normandy University, 14000 Caen, FranceAim: To perform a comprehensive analysis of discordances between contrast-enhanced CT (ceCT) and <sup>18</sup>F-FDG PET/CT in the evaluation of the extra-cerebral treatment monitoring in patients with stage IV melanoma. Materials and methods: We conducted a retrospective monocentric observational study over a 3-year period in patients referred for <sup>18</sup>F-FDG PET/CT and ceCT in the framework of therapy monitoring of immune checkpoint (ICIs) as of January 2017. Imaging reports were analyzed by two physicians in consensus. The anatomical site responsible for discordances, as well as induced changes in treatment were noted. Results: Eighty patients were included and 195 pairs of scans analyzed. Overall, discordances occurred in 65 cases (33%). Eighty percent of the discordances (52/65) were due to <sup>18</sup>F-FDG PET/CT scans upstaging the patient. Amongst these discordances, 17/52 (33%) led to change in patient’s management, the most frequent being radiotherapy of a progressing site. ceCT represented 13/65 (20%) of discordances and induced changes in patients’ management in 2/13 cases (15%). The most frequent anatomical site involved was subcutaneous for <sup>18</sup>F-FDG PET/CT findings and lung or liver for ceCT. Conclusions: Treatment monitoring with <sup>18</sup>F-FDG PET/CT is more efficient than ceCT and has a greater impact in patient’s management.https://www.mdpi.com/2075-4418/11/7/1198<sup>18</sup>F-FDG PET/CTcontrast-enhanced CTmelanomametastasestyrosine kinase inhibitorsImmune checkpoint inhibitors |
| spellingShingle | Jean-Baptiste Le Goubey Charline Lasnon Ines Nakouri Laure Césaire Michel de Pontville Catherine Nganoa Diane Kottler Nicolas Aide <sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital Diagnostics <sup>18</sup>F-FDG PET/CT contrast-enhanced CT melanoma metastases tyrosine kinase inhibitors Immune checkpoint inhibitors |
| title | <sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital |
| title_full | <sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital |
| title_fullStr | <sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital |
| title_full_unstemmed | <sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital |
| title_short | <sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital |
| title_sort | sup 18 sup f fdg pet ct versus diagnostic contrast enhanced ct for follow up of stage iv melanoma patients treated by immune checkpoint inhibitors frequency and management of discordances over a 3 year period in a university hospital |
| topic | <sup>18</sup>F-FDG PET/CT contrast-enhanced CT melanoma metastases tyrosine kinase inhibitors Immune checkpoint inhibitors |
| url | https://www.mdpi.com/2075-4418/11/7/1198 |
| work_keys_str_mv | AT jeanbaptistelegoubey sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital AT charlinelasnon sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital AT inesnakouri sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital AT laurecesaire sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital AT micheldepontville sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital AT catherinenganoa sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital AT dianekottler sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital AT nicolasaide sup18supffdgpetctversusdiagnosticcontrastenhancedctforfollowupofstageivmelanomapatientstreatedbyimmunecheckpointinhibitorsfrequencyandmanagementofdiscordancesovera3yearperiodinauniversityhospital |